HFA
MRNA icon

HC Financial Advisors’s Moderna MRNA Stock Holding History

HC Financial Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$14K Buy
+100
New +$14.3K 0.01% 213

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HC Financial Advisors's MRNA Position: Q2 2022 in Review

HC Financial Advisors opened a new position in Moderna (MRNA) in Q2 2022: 100 shares worth $14K. The stake represents 0.01% of the portfolio and ranks #213 among its holdings.

982 funds tracked by Wall St. Rank hold MRNA as of Q2 2022.

  • HC Financial Advisors held 100 shares of Moderna worth $14K as of Q2 2022.
  • Moderna was a new HC Financial Advisors position in Q2 2022.
  • Moderna made up 0.01% of HC Financial Advisors's portfolio in Q2 2022, its #213 holding.
  • 982 funds tracked by Wall St. Rank held Moderna as of Q2 2022.

Based on HC Financial Advisors's 13F filing for Q2 2022, filed 25 Jul 2022.